BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25101911)

  • 1. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
    J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
    Sekimata K; Sato T; Sakai N
    Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
    Yamamoto H; Sakai N; Ohte S; Sato T; Sekimata K; Matsumoto T; Nakamura K; Watanabe H; Mishima-Tsumagari C; Tanaka A; Hashizume Y; Honma T; Katagiri T; Miyazono K; Tomoda H; Shirouzu M; Koyama H
    Bioorg Med Chem Lett; 2021 Apr; 38():127858. PubMed ID: 33609658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
    Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
    Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva.
    Ullrich T; Arista L; Weiler S; Teixeira-Fouchard S; Broennimann V; Stiefl N; Head V; Kramer I; Guth S
    Bioorg Med Chem Lett; 2022 May; 64():128667. PubMed ID: 35276359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
    Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
    Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
    Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
    Luo Y; Alsamarah A; Zhang K; Hao J
    Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
    Williams E; Bullock AN
    Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of small molecule inhibitor of BMP signaling.
    Sanvitale CE; Kerr G; Chaikuad A; Ramel MC; Mohedas AH; Reichert S; Wang Y; Triffitt JT; Cuny GD; Yu PB; Hill CS; Bullock AN
    PLoS One; 2013; 8(4):e62721. PubMed ID: 23646137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.
    Engers DW; Bollinger SR; Felts AS; Vadukoot AK; Williams CH; Blobaum AL; Lindsley CW; Hong CC; Hopkins CR
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127418. PubMed ID: 32750526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
    Takahashi M; Katagiri T; Furuya H; Hohjoh H
    Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in drug development for fibrodysplasia ossificans progressiva.
    Meng X; Wang H; Hao J
    Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
    Davis AJ; Brooijmans N; Brubaker JD; Stevison F; LaBranche TP; Albayya F; Fleming P; Hodous BL; Kim JL; Kim S; Lobbardi R; Palmer M; Sheets MP; Vassiliadis J; Wang R; Williams BD; Wilson D; Xu L; Zhu XJ; Bouchard K; Hunter JW; Graul C; Greenblatt E; Hussein A; Lyon M; Russo J; Stewart R; Dorsch M; Guzi TJ; Kadambi V; Lengauer C; Garner AP
    Sci Transl Med; 2024 May; 16(749):eabp8334. PubMed ID: 38809966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.
    Pacifici M; Shore EM
    Cytokine Growth Factor Rev; 2016 Feb; 27():93-104. PubMed ID: 26776312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drosophila models of FOP provide mechanistic insight.
    Le V; Anderson E; Akiyama T; Wharton KA
    Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.